Healthcare Industry News: REVLIMID
News Release - June 12, 2006
Proprius Pharmaceuticals Appoints David W. Anderson, Ph.D. as Chief Scientific OfficerSAN DIEGO, June 12 (HSMN NewsFeed) -- Proprius Pharmaceuticals, Inc. today announced that David W. Anderson, Ph.D. has joined the company in the role of Chief Scientific Officer. Dr. Anderson is a seasoned executive with 25 years of experience identifying and pursuing innovative approaches to drug discovery and clinical development. Dr. Anderson has previously held a variety of key management positions, including Chief Scientific Officer at Celgene Corporation/Signal Research Division, Senior Vice President of Research & Development at Signal Pharmaceuticals, Senior Director of Drug Discovery and Experimental Therapeutics at Johnson & Johnson (J&J), Director of the J&J Labs at Scripps Research Institute, and Group Leader at Monsanto/GD Searle.
During his career, Dr. Anderson has been responsible for ushering numerous drugs into the clinic, and has made important development contributions to four drugs approved by the FDA, including J&J's Procrit® (erythropoietin), a product that achieved peak annual sales of over $4 billion, and Celgene's REVLIMID® (lenalidomide), a drug recently approved by the FDA. While Director of the J&J Labs at Scripps, Dr. Anderson identified and sponsored a number of drugs and technologies that led to the creation of three separate biotechnology companies.
Dr. Anderson holds a Ph.D. in Medical Microbiology and Immunology from the University of Missouri-Columbia. In addition to authoring numerous publications and patents, Dr. Anderson has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti- inflammatory and immunomodulatory drugs. He has also refereed articles for peer-reviewed journals such as Science and The Journal of Rheumatology.
"We are delighted to add Dr. Anderson to our team," said Michael J. Walsh, President and CEO of Proprius. "Not only does he bring a deep knowledge of rheumatology and autoimmune diseases and a proven track record in drug discovery and development, but a real passion for developing therapies that will improve the care of people suffering from chronic debilitating diseases. In addition, David has a strong ability to identify promising therapeutic approaches and to execute on innovative clinical development strategies."
"Proprius is an ideal fit for my background and interests," said Dr. Anderson, "and I look forward to joining a management team with an impressive record of accomplishment. Proprius' strategy of offering both therapeutic interventions and, where appropriate, clinical diagnostics, is quite compelling and has the potential to dramatically improve the state of care for patients suffering from inflammatory and autoimmune diseases. In addition," continued Dr. Anderson, "Indaflex(TM) 2.5% Indomethacin Cream, a topical NSAID currently in phase II clinical trials, is a very exciting lead product that could benefit millions of patients suffering from osteoarthritis of the knee and other related disorders. Indomethacin is as potent a pain reliever as morphine, but can cause gastrointestinal problems when taken orally. Indomethacin is an ideal candidate for topical delivery, but its extreme insolubility has historically hampered formulation efforts. AlphaRx, Proprius' partner on Indaflex, developed a proprietary oil-in-water microemulsion formulation to overcome this problem, which delivers a high concentration of indomethacin through the skin with negligible amounts of the drug entering the circulatory system. I am eager to help move Indaflex forward and to identify additional opportunities for therapeutic and diagnostic solutions in this important area."
About Proprius Pharmaceuticals, Inc.
Proprius Pharmaceuticals is a fully-integrated specialty pharmaceutical company that develops and markets personalized medicine solutions in rheumatology and autoimmune diseases. This novel combination of proprietary therapeutics and diagnostic services provides a strategic and differentiated approach to commercialization. Proprius is a privately-held and venture- backed organization, with financing provided by Fog City Fund, LLC, and Windamere Venture Partners, LLC.
Source: Proprius Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.